Novo Nordisk Maps 20-Market Wegovy Pill Push as Mexico Rollout Tests Oral Bet
Published on 11/12/2026 at 17:53 | Editorial boerse-global.de
Novo Nordisk has set its sights on putting the Wegovy pill on pharmacy shelves in at least 20 countries by the end of 2027, chief executive Mike Doustdar told Danish broadcaster DR. Denmark is on the list, with the company signalling a launch there before the close of next year — though a firm date, price and reimbursement terms have yet to be disclosed.
The tablet is already sold in the US, the UK, the United Arab Emirates and Germany. In Denmark it is currently reachable only through parallel imports, so an official rollout would reshape access. How much revenue that generates will hinge on the pricing and coverage conditions still under negotiation.
Doustdar, speaking on DR, also addressed shareholder losses, describing the rebuilding of trust as a marathon. The international launch of the pill, he indicated, is one concrete test of whether Novo can deliver the market presence it has promised.
Mexico Opens the Latin American Account
The company brought Wegovy tablets to Mexico yesterday, its first market in Latin America. Mexican regulator COFEPRIS cleared the product in August, and availability is set to widen over the coming weeks to an estimated 10,000 points of sale. Novo pegs the potential market at 7.5 million people.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Execution now becomes the next checkpoint. Novo's own survey found that more than 77% of adults would be more inclined to start treatment if it came as a tablet, yet fewer than 1% of people with overweight or obesity in Mexico currently receive any such care. The survey points to appetite for the format — provided that stated willingness converts into prescriptions. Pricing is meant to be competitive and close to the injectable version, varying by dose and outlet, and a prescription plus medical supervision remain mandatory.
Clinical evidence underpins the entry. In the Phase 3 OASIS 4 trial, participants lost roughly 17% of body weight after 64 weeks. The approval covers long-term weight reduction in adults with obesity, or with overweight plus a weight-related comorbidity, and extends to cutting the risk of major cardiovascular events in adults with established cardiovascular disease and overweight or obesity. Since the Wegovy pill first launched, cumulative prescriptions have passed 8 million.
The Pill Is Carrying More of the Growth
In the third quarter of 2026, the Wegovy tablet generated DKK 5.4 billion in revenue, while total obesity sales climbed 22% — giving the oral therapy real weight in Novo's business trajectory. That is what makes the expansion push matter: extra markets can broaden the revenue base if demand there can be served at economically viable prices. The existing portfolio, meanwhile, remains under pressure from falling net prices.
According to an analysis published today, group revenue would have fallen by about 2% without the Wegovy pill. The same analysis puts net price declines at 10–15% for Ozempic and 30–35% for Wegovy. The growth contribution of the new dosage form therefore counts for Novo only as long as its added volume can offset the drag elsewhere.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
China Hands Lilly the Inside Track
China illustrates how hard-fought the international race is. Reuters reported that Eli Lilly has secured the first approval there for a GLP-1 weight-loss pill, while Novo's application for the oral Wegovy version is still awaiting a decision. J.P. Morgan expects the Chinese GLP-1 market for weight treatment to reach annual sales of 30 billion yuan within five to seven years.
That market offers Novo an additional growth avenue if approval lands and a competitive route to patients follows. Until then, the announced international build-out faces a concrete head start by its rival. The test for Doustdar's plan thus runs on two tracks at once: how many launches Novo actually completes, and how much profit each one delivers.
Ad
Novo Nordisk Stock: New Analysis - 12 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
